ELYVOPE
Live / Applied — Fifth extension granted (statement of use) (as of 26 Jan 2026)
What this means for you
Not registered yet, but its 27 Aug 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90906331
- Mark type
- Stylized text
- Filed
- 27 Aug 2021
- Published for opposition
- 24 Jan 2023
- Attorney of record
- Carissa L. Weiss
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders
- Class 035 — Advertising and business services: Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals
- Class 042 — Scientific and technological services: Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
- Class 044 — Medical, beauty and agricultural services: Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders
Owner
- ACADIA Pharmaceuticals, Inc., San Diego, CA, US
- ACADIA Pharmaceuticals, Inc., San Diego, CA, US
Prosecution history
- 27 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jan 2026 — SOU EXTENSION 5 GRANTED
- 04 Sept 2025 — SOU EXTENSION 5 FILED
- 26 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 05 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Mar 2025 — SOU EXTENSION 4 GRANTED
- 19 Mar 2025 — SOU EXTENSION 4 FILED
- 19 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Sept 2024 — SOU EXTENSION 3 GRANTED
- 04 Sept 2024 — SOU EXTENSION 3 FILED
- 04 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 17 May 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 May 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED